Analysis of the binding sites of vitamin D 1α-hydroxylase (CYP27B1) and vitamin D 24-hydroxylase (CYP24A1) for the design of selective CYP24A1 inhibitors: homology modelling, molecular dynamics simulations and identification of key binding requirements by Taban, Ismail M. et al.
1 
 
Analysis of the binding sites of vitamin D 1-hydroxylase (CYP27B1) and 
vitamin D 24-hydroxylase (CYP24A1) for the design of selective CYP24A1 
inhibitors: homology modelling, molecular dynamics simulations and 
identification of key binding requirements 
 
Ismail M. Taban,a Jinge Zhu,b Hector F. DeLucab and Claire Simonsa* 
 
aMedicinal Chemistry, School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King 
Edward VII Avenue, Cardiff CF10 3NB, UK; bDepartment of Biochemistry, University of 
Wisconsin-Madison, 433 Babcock Drive, Madison, WI 53706-1544, USA. 
 
 
 
 
Corresponding author: Tel.: +44 (0) 2920 876307; fax: +44 (0) 2920 874149. 
E-mail address: simonsc@cardiff.ac.uk (C. Simons) 
 
 
 
 
 
 
 
 
 
2 
 
 
Abstract 
A homology model of human CYP27B1 was built using MOE and ith further optimisation by 
molecular dynamics simulations of the hCYP27B1 homology model and a hCYP27B1-SDZ-88357 
complex. Docking results from the hCYP27B1-SDZ-88357 complex showed amino acids Arg107, 
Asn387 and Asp320 have an important role in binding interaction, with Asp320 part of the 
important acid - alcohol pair situated in the I-helix with the conserved sequence (A/G) GX (E/D) 
(T/S), which assumes an essential role in the binding of an oxygen molecule for catalysis. 
Additional docking experiments with selective hCYP27B1 or hCYP24A1 inhibitors using both the 
hCYP27B1 model and a triple mutant hCYP24A1 model provided further support for the 
importance of H-bonding interactions with the three identified active site amino acids.  To confirm 
the role of Arg107, Asn387 and Asp320 in the active site of hCYP27B1 compounds were designed 
that would form H-bonding interactions, as determined from docking experiments with hCYP27B1 
model. Subsequent synthesis and CYP24A1 and CYP27B1 enzyme assays of the designed 
compounds 1a and 1b showed a ~ 5-fold selectivity for CYP27B1 confirming the importance of 
Asp320 in particular and also Asn387 and Arg107 as important amino acids for CYP27B1 
inhibitory activity.  
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1. Introduction 
Calcitriol (1,25-dihydroxyvitamin D3) is the biologically active form of vitamin D, with deficiency 
of calcitriol in human linked to defects in bone formation and mineralisation, for example, rickets in 
children and osteomalacia in adults1. CYP27B1 (vitamin D 1α–hydroxylase), which is expressed 
primarily in the kidney2 but is also found in other organs,3 produces calcitriol by 1-hydroxylation 
of 25-hydroxyvitamin D3 (Figure 1).  
 
Figure 1. Vitamin D metabolic pathway 
 
Calcitriol subsequently binds to the vitamin D receptor (VDR) to enhance production of target 
genes4,5. Calcitriol is subject to metabolic transformation to inactive polar metabolites by the action 
of CYP24A1 (vitamin D 24-hydroxylase). Under normal conditions levels of CYP27B1 and 
CYP24A1, and therefore the levels of calcitriol, are tightly controlled through the action of 
parathyroid hormone and fibroblast growth factor-236,7. However, increased levels of CYP24A1 
have been observed in a number of human cancers including breast8, colon9, prostate10 and skin 
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cancers11, directly correlating with a reduction in circulating calcitriol. To enhance circulating levels 
of the biologically active form of vitamin D, CYP24A1 inhibitors have been developed12-19 and, 
although potent inhibitors with IC50 values in the nanomolar range have been described, one of the 
biggest challenges has been designing inhibitors selective for CYP24A1 over CYP27B1. A few 
azole inhibitors with good selectivity have been described, notably (R)-VID40012 which is ~ 40-fold 
more selective for CYP24A1 compared with CYP27B1 and the SDZ compounds, SDZ-8835712 and 
SDZ-28508213, which are ~ 166-fold and 47-fold respectively more selective for CYP27B1 over 
CYP24A1 (Fig. 2). 
                     
               (R)-VID400        SDZ-88357                 SDZ-285082 
    CYP24A1 IC50 15.2 nM  CYP24A1 IC50 >10 M  CYP24A1 IC50 4.48 M  
    CYP27B1 IC50 616.1 nM             CYP27B1 IC50 60.2 nM          CYP27B1 IC50 95.2 nM 
 
Figure 2. CYP24A1 and CYP27B1 selective azole inhibitors  
 
To date crystal structures for human CYP24A1 (hCYP24A1) and human CYP27B1 (hCYP27B1) 
have not been resolved. A model of hCYP24A1 using the rat CYP24A1 (rCYP24A1) crystal 
structure as a template has previously been described by our group14,20. To assist in the design of a 
selective CYP24A1 inhibitor, a human hCYP27B1 homology model was required in order to 
analyse any differences between active site architecture and binding interactions of the two 
enzymes. A hCYP27B1 hybrid homology model, built by combining models generated from 
rCYP24A1 and hCYP11A1 crystal structures as templates, has been described by Zalewski et al21 
in their investigation of mutations in hCYP27B1 related to vitamin D dependent rickets type I. In a 
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similar manner suitable templates were identified and homology models were generated for our 
research but with the focus on active site binding/architecture for the purpose of drug design. 
 
2. Results and discussion 
2.1 Generation of the hCYP27B1 homology model 
Using the UniProt KB/TrEMBL server (ExPASy)22 the complete human CYP27B1 protein 
sequence (entry number O15528), composed of 508 amino acids, was selected. A protein-protein 
BLAST23 (ncbi) search was run against the Protein Databank (PDB)24 to identify homologous 
crystal structures. The most homologous templates were rCYP24A1 and hCYP11A1 with 33% 
sequence identity, however the rCYP24A1 template had greater sequence coverage, higher BLAST 
score and E-value (Table 1). 
 
Table 1 The first four hits in the human CYP27B1 BLAST results 
Organism PDB 
code 
BLASTa 
score 
Sequence 
identityb 
Sequence 
identity% 
Positive 
% 
Chain 
length 
E-
Value 
CYP24A1 (rat) 3K9V 263 160/478 33 50 482 4e-82 
CYP11A1 (human) 3N9Y 254 155/474 33 49 487 2e-78 
CYP11B2 (human) 4DVQ 197 136/415 33 47 483 7e-57 
CYP3A4 (human) 1W0E 152 134/494 27 45 485 4e-40 
a The BLAST score for an alignment is calculated by summing the scores for each aligned position and the scores for 
gaps. b (Number of identical residues)/(length of sequence fragment identified by BLAST-P). 
 
Clustal Omega 1.2.225 was used to align the preferred template sequences and the query sequence of 
hCYP27B1 (Fig. 3). Conservation was clearly observed between most of the residues of the query 
sequence and the closely related templates in the active site region, which encompasses the haem 
binding domain typically sandwiched between helix L on the side of the haem proximal to the 
surface of the protein and helix I in the inside of the protein as well as the important acid-alcohol 
pair situated in the I-helix with the conserved sequence (A/G) GX (E/D) (T/S) (Fig. 3).  
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      H HELIX acid-alcohol I Helix        J Helix 
CYP11A1      LGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQ--A 323 
CYP27B1      LFREELPAQSILGNVTELLLAGVDTVSNTLSWALYELSRHPEVQTALHSEITAALSPGSS 356 
CYP24A1      YQQDHLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQAQRRLLQEVQSVLPD--N 331 
                ..:  :.: . ***:  ..*:*.: :* * **:::*: :.*  *  *: :.      
  
        K HELIX       1-4 2-1  1-3 
CYP11A1      QGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIYALG 383 
CYP27B1      AYPSATVLSQLPLLKAVVKEVLRLYPVVPGNSRVPDKDIHVGDYIIPKNTLVTLCHYATS 416 
CYP24A1      QTPRAEDLRNMPYLKACLKESMRLTPSVPFTTRTLDKPTVLGEYALPKGTVLTLNTQVLG 391 
                 *  *  :* *** :** :** *      *   :   : :* :*  *:: :   . . 
          
          Haem pocket      L-HELIX 
CYP11A1      REPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINMLENF 443 
CYP27B1      RDPAQFPEPNSFRPARWLGEGPTPHPFASLPFGFGKRSCMGRRLAELELQMALAQILTHF 476 
CYP24A1      SSEDNFEDSHKFRPERWLQKEKKINPFAHLPFGIGKRMCIGRRLAELQLHLALCWIIQKY 451 
              .   * : ..* * *** :  .   *  * ** * * *:***:***:: : *  :: :: 
 
Figure 3. CLUSTAL alignment of the active site region of the hCYP27B1 protein sequence against 
rCYP24A1 and hCYP11A1 human protein sequences. Asterisk identical residues, colon highly conserved 
residues, dot residues are somewhat similar. The residues are colored according to their chemical properties: red small 
hydrophobic (AVFPMILWY), blue acidic (DE), magenta basic (RHK), green hydroxyl + amine + basic (STYHCNGQ) 
 
Homology models using both rCYP24A1 and hCYP11A1 were generated using MOE software and 
based on validation results using Ramachandran plots26, Verify 3D27 and ProSA28, as well as 
BLAST analysis and consideration of template enzyme function, the homology model from 
rCYP24A1 as template was chosen for further optimisation and docking studies. 
 
2.2 Molecular dynamics studies 
Further optimisation of the active site architecture was achieved by molecular dynamics 
simulations, using the Desmond programme of Maestro29, carried out at two different temperatures, 
300 K and 312 K. Molecular dynamics simulation at 300 K and 312 K represent normal body 
temperature and elevated body temperature.  
2.2.1 Molecular dynamics of hCYP27B1 model at 300K 
The RMSD values of the backbone atoms were plotted as a time-dependent function of the 
molecular dynamics simulation. The outcomes support the CYP27B1 model structure, as they show 
time dependence of constant RMSD (Å) of the backbone atoms throughout the whole simulation 
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process. This demonstrates that the model achieved equilibrium after some initial fluctuations. The 
chart plainly shows that there is an adjustment in the RMSD from 0.9 Å to 2.4 Å and that it reached 
2.02 Å at 1.39 ns and then declined to 1.83 Å at 1.83 ns, but after that, it reached a plateau from 
2.25 ns (Figure 4A and 4B).  
 
A       B 
 
C        D 
 
Figure 4. (A) Time-dependent RMSD (Å) of backbone atoms of the CYP27B1 model at 300 K (B) 
Root mean square fluctuation (RMSF) showed the differences of structural behaviours and 
flexibilities in each residue for the CYP27B1 model; the amino acid residue (Pro440) was shown to 
be highly fluctuated. (C) Time-dependent RMSD (Å) of backbone atoms of the CYP27B1 model at 
312 K (D) Root mean square fluctuation (RMSF) showed the differences of structural behaviours 
and flexibilities in each residue for the CYP27B1 model; the amino acid residue (Gly281) was 
shown to be highly fluctuated. 
 
 
2.2.2 Molecular dynamics of hCYP27B1 model at 312 K 
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The RMSD of the backbone atom values for CYP27B1 at 312 K simulations were not much 
different from the simulations at 300 K. However, the graph clearly indicates that there is a change 
in the RMSD from 0.9 Å to 2.5 Å, and it reaches a plateau from 2.48 ns (Fig. 4C and 4D). Overall, 
it can be said that there is no significant difference in structure during molecular dynamics 
simulations at temperatures 300 K and 312 K. This means that at 312 K, the model still has activity, 
and no structural damage has occurred. 
To validate the optimised hCYP27B1 model structure, Ramachandran plots were run before as well 
as after molecular dynamics simulation. The number of outlier amino acids after molecular 
dynamics was 5 (1.1%) compared with 12 (2.5%) amino acid outliers prior to molecular dynamics. 
The five outliers were found to be in the outer regions of the protein within loops, which are very 
difficult to model, and away from the active site. 
2.2.3. Molecular dynamic simulation of the hCYP27B1-SDZ-88357 complex at 300 K  
A molecular dynamics simulation of the hCYP27B1 model complexed with the CYP27B1 selective 
inhibitor SDZ-88357 was run for 50 ns. The RMSD changed from 1.37 Å at zero time to 3.57 Å at 
33.44 ns; then the protein was equilibrated with no evident RMSD fluctuations observed after 
33.44 ns. Ligand RMSD (right Y- axis, Fig. 5) demonstrates how stable the ligand is regarding the 
protein and its binding pocket. The red line indicates the RMSD of a ligand when the hCYP27B1-
SDZ-88357 complex is initially aligned on the protein backbone of the reference and then the 
RMSD of the ligand heavy atoms is measured. A pink line (Lig fit Lig) indicates the RMSD of a 
ligand that is aligned and measured just on its reference conformation (Fig. 5). This RMSD value 
measures the internal fluctuations of the ligand atoms. 
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Figure 5: Protein and ligand root mean square fluctuation (RMSF) of the hCYP27B1-SDZ-88357 
complex. 
  
Protein interactions with the ligand were checked throughout the simulation and interactions are 
ordered by their type; specifically hydrogen bonds, hydrophobic, ionic, and water bridges (Fig. 6).  
 
Figure 6.  Illustration of protein interactions with the ligand. The red column means ionic bond, 
green column a hydrogen bond, blue column water bridges, and a purple column a hydrophobic 
bond. The stacked bar charts are normalised over the course of the trajectory: for example, a value 
of 0.5 suggests that for 50% of the simulation time, the specific interaction is maintained. 
 
 
Interaction between the nitrogen lone pair of the tetrazole ring of SDZ-88357 and the haem iron at a 
distance of 2.25 Å was observed with hydrophobic interactions with amino acid residues in the 
active site (Phe110, Leu127, Pro385 and Gly386) (Fig. 7). In addition, SDZ-88357 was observed 
making three additional hydrogen bonds with amino acids Arg107, Asn387 and Asp320.  
 
Figure 7.  3D and 2D images showing interactions between SDZ-88357 and hCYP27B1 active site  
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Asp320 is included in the acid - alcohol pair situated in the I-helix with the conserved sequence 
(A/G) GX (E/D) (T/S), which assumes an essential role in the binding of an oxygen molecule for 
catalysis. In contrast (R)-VID400, a selective CYP24A1 inhibitor, on docking in the hCYP27B1 
optimised model was positioned unfavourably at too great a distance from the haem iron (4.16 Å) to 
form an interaction with the imidazole ring of this CYP24A1 inhibitor, and no H-bonding 
interaction formed with the hydrophobic 4-chlorobiphenyl side chain (Fig. 8A and B). However 
SDZ-285082 docked favourably with hydrogen bonding interactions with Arg107 and Asn387 as 
observed for SDZ-88357 (Fig. 8C and D). 
A B 
  
C D 
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Figure 8.  (A) 3D image of (R)-VID400 in CYP27B1 active site (B) 2D image (R)-VID400 in 
CYP27B1 active site (C) 3D image of SDZ-285092 in CYP27B1 active site (B) 2D image SDZ-
285092 in CYP27B1 active site 
 
2.2.4 Docking of SDZ-88357 in the hCYP24A1 model and a triple mutant hCYP24A1 model 
 
Schuster et al.4 showed that SDZ-88357 was a very weak inhibitor of the CYP24A1 enzyme (> 10 
M). Docking results with our hCYP24A1 model concur with experimental data with the distance 
between the nitrogen lone pair of tetrazole and the haem iron at a distance of 5.56 Å, that is, too far 
a distance for interaction.  
A B 
  
                                                        C 
 
Figure 9. Docking of (A) SDZ-88357 and (B) SDZ-285082 and (C) (R)-VID400 in the hCYP24A1 
model active site  
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There were multiple hydrophobic interactions between the SDZ-88357 with amino acid residues in 
the active site (Arg128, Leu129, Ile131, Trp134, Leu148, Met246, Phe249, Leu325, ala326, 
Val391, Pro392, Phe393, Thr395, His497, Gly499 and Thr500) (Fig. 9A) but no hydrogen bonding 
interactions within the hCYP24A1 hydrophobic active site cavity. SDZ-285082 docked in a similar 
manner and was also positioned too far from the haem iron (4.15Å) to interact (Fig. 9B). This was 
in contrast with (R)-VID400 with the distance between the nitrogen of imidazole and the haem iron 
observed as 2.31Å (Fig. 9C).   
To explore the potential importance of H-bonding interactions in the inhibitory activity and 
selectivity of SDZ-88357 in hCYP27B1, a computational triple hCYP24A1 mutant was generated 
using MOE software30. After alignment of the hCYP24A1 and hCYP27B1 3D models, amino acids 
of hCYP24A1 that were comparable in position with Arg107, Asp320 and Asn387 were identified 
and mutated as follows: L148A, H497R and G499N. Subsequent docking of SDZ-88357 in the 
triple mutant hCYP24A1 model resulted in favourable interaction with the haem (distance 2.38 Å) 
and additional hydrogen bonding interactions (Figure 10).  
            
Figure 10: 3D and 2D docking images of SDZ-88357 in the triple mutant hCYP24A1 active site  
 
From these computational studies the requirement for CYP24A1 selectivity is linked with 
hydrophobic pharmacophores, whilst CYP27B1 selectivity is linked with pharmacophores capable 
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of hydrogen and/or ionic bonding interactions. To further confirm this compounds containing the 
pharmacophores necessary for haem binding and hydrogen/ionic bonding interactions combined 
with the classic T- or Y-shaped inhibitor shape were required.  
 
2.3 Design and synthesis of hCYP27B1 inhibitors  
With the new findings regarding hCYP24A1 vs hCYP27B1 requirements for selectivity, further 
evaluation of optimal pharmacophores was reconsidered and through combining key binding 
requirements (haem binding, H-bonding functional group) the 4,4'-((3/4-(pyridin-4-
ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) structures (1a and 1b) were designed 
to explore binding/inhibition profiles. 1a and 1b displayed interesting results in the docking 
experiments with hCYP24A1 and hCYP27B1 and could be generated using a short efficient 
synthetic route.  
A 
                                      
     
B 
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Figure 11: 3D and 2D docking images of 1a in the (A) hCYP24A1 model, and (B) hCYP27B1 
model.  
 
When 1a and 1b were docked in the hCYP24A1 model, interaction with the haem iron was through 
the pyridyl nitrogen with hydrogen bonding with Arg128, Leu129, Glu130, Leu148 and Thr395 as 
illustrated in Figure 11A. The docking would predict CYP24A1 inhibitory activity, with the longer 
pyridin-4-ylmethoxy group allowing close binding with the haem, however the hydrophilic 
functional groups with resulting hydrogen bonding would suggest CYP27B1 inhibitory activity. 
Docking of 1a and 1b in the hCYP27B1 model did indicate good fit, hydrogen bonding interactions 
(Asp320 and Asn387, identified as important for CYP27B1 inhibitory activity) and haem binding, 
although in the hCYP27B1 model haem binding was optimal through a pyrazole nitrogen (Fig. 
11B). 
 
The designed compounds (1) were readily obtained in two steps. The 3/4-(pyridine-4-
ylmethoxy)benzaldehydes (3) were prepared as previously described31 on reaction of 3/4-
hydroxybenzaldehyde (2) with potassium carbonate and 4-(chloromethyl)pyridine hydrochloride. 
Reaction of the 3/4-(pyridine-4-ylmethoxy)benzaldehydes (3) with hydrazine hydrate and ethyl 
acetoacetate, employing 2-hydroxy ethylammonium propionate (2-HEAP32) as the catalyst, gave the 
required 4,4'-((3/4-(pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) 
derivatives (1a and 1b) (Scheme 1). 
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Scheme 1. Reagents and conditions: (i) K2CO3, DMF, 4-(chloromethyl)pyridine hydrochloride, 80 
oC, 7h  (ii) H2NNH2, ethyl acetoacetate, 2-HEAP, 90 
oC, 1 h. 
 
2.4 CYP24A1 and CYP27B1 enzymatic assay 
The CYP24A1 enzymatic assay followed methodology previously described33. In short, human 
CYP24A1 with an N-terminal fusion to maltose binding protein (MBP) was overexpressed in 
Escherichia coli and purified to homogeneity. The hydrolase activity was reconstituted in vitro, and 
the resulting cell-free assay system was applied in the screening of the compounds to measure IC50  
The inhibition assay of CYP27B1 was similar to the CYP24A1 assay as previously described33, and 
the resulting cell-free assay system was applied in the screening of the compounds to measure IC50. 
The main difference between 1a and 1b was changing the position of the ether group from the para 
position to the meta position on the phenyl ring, but it resulted in no notable difference in 
CYP24A1 or CYP27B1 inhibitory activity. 1a and 1b displayed modest CYP24A1 inhibitory 
activity  compared with the standard ketoconazole (KTZ, IC50 0.5 
M), however as expected from docking they displayed potent CYP27B1 inhibitory activity 
comparable with KTZ (IC50 0.34 M) with IC50 0.57 and 0.41 M respectively. 
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Figure 12. hCYP24A1 and hCYP27B1 inhibitory activity  
 
1a and 1b have selectivity for CYP27B1 that is ~ 5-fold greater than CYP24A1 (Fig. 12). The 
selectivity of 1a and 1b can be rationalised by better fit and binding in the hCYP27B1 active site, 
where the pyrazole ring interacted with the haem iron in addition to formation of hydrogen bonds 
with Asp320 and Asn387, which are important amino acids in hCYP27B1. 
 
3. Conclusions 
A homology model of CYP27B1 was built using MOE and was evaluated for stereochemical and 
amino acid environment quality using appropriate programmes, with further optimisation of the 
active site architecture achieved by molecular dynamics simulations. Understanding protein-ligand 
interactions is essential for designing more selective and potent CYP24A1 inhibitors. This work 
uses a combination of homology modelling, molecular dynamics simulations, and molecular 
docking to understand the binding requirements of the hCYP27B1 enzyme. Docking results from 
the hCYP27B1-SDZ-88357 complex showed amino acids Arg107, Asn387 and Asp320 have an 
important role in binding interaction. Asp320 was part of the αI helix for the CYP27B1 model, 
which covers the haem binding site and contains SRS-4, and plays a key role in orientating the 
0
0.5
1
1.5
2
2.5
3
1a 1b KTZ
CYP24A1
CYP27B1
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ligand at the active site by electrostatic interactions. Asp320 has the important acid - alcohol pair 
situated in the I-helix with the conserved sequence (A/G) GX (E/D) (T/S), which assumes an 
essential role in the binding of an oxygen molecule for catalysis. The main strategy that can be used 
to build inhibitors selective for CYP24A1 over CYP27B1, is to design compound unable to form 
hydrogen bonding interactions with CYP27B1 especially with Arg107, Asn387 and Asp320. To 
confirm the role of Arg107, Asn387 and Asp320 in the active site of hCYP27B1 compounds were 
designed that would form hydrogen bonding interactions, as determined from docking experiments 
with hCYP27B1. Subsequent synthesis and CYP24A1 and CYP27B1 enzyme assays of the 
designed compounds 1a and 1b showed a ~ 5-fold selectivity for CYP27B1 confirming the 
importance of Asp320 in particular and also Asn387 and Arg107 as important amino acids for 
CYP27B1 inhibitory activity.  
Although additional H-bonds can improve binding and potentially inhibitory activity of hCYP24A1 
this is at the expense of selectivity. Incorporating larger hydrophic pharmacophores capable of 
filling the active site cavity and formation of multiple hydrophic interactions with active site amino 
acids would result in CYP24A1 inhibitory activity and crucially selectivity with respect to 
CYP27B1. 
 
4. Experimental 
4.1 General Experimental 
1,25(OH)2D3 and 25(OH)D3 were purchased from SAFC-Pharma (Madison, WI). Human MBP-
CYP24A1, CYP27B1, bovine adrenodoxin (Adx), and adrenodoxin reductase (AdR) were purified 
as described previously33. All solvents used for chromatography were HPLC grade from Fisher 
Scientific (UK).  
1H and 13C NMR spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 
500 and 125 MHz, with Me4Si as internal standard. Mass spectra and microanalysis were 
determined by the MEDAC (Chobham, UK). Flash column chromatography was performed with 
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silica gel 60 (230-400mesh) (Merck) and TLC was carried out on precoated silica plates (kiesel gel 
60 F254, BDH). Compounds were visualised by illumination under UV light (254 nm) or by the use 
of vanillin stain followed by charring on a hotplate. Melting points were determined on an 
electrothermal instrument and are uncorrected. All solvents were dried prior to use and stored over 
4Å molecular sieves, under nitrogen. All compounds were more than 95% pure. 
4.2 Molecular modelling 
4.2.1 Homology search 
The protein sequence for hCYP27B1 was obtained from the ExPASy proteomics server at the Swiss 
Bioinformatics Institute22. The enzyme sequence for the hCYP27B1 has the Uniprot identifier 
O15528 and is composed of 508 amino acids. A homology search was performed using protein 
BLAST accessible from the NCBI website23, which was used to align the query sequence 
(hCYP27B1) against the sequences in the protein data bank24 and thus the close homologous 
proteins were identified. The alignment parameters and the thresholds, which were used for 
screening expected homologues, were used with their default values and BLOSUM62 comparison 
matrix.  
4.2.2. 3D model building 
The molecular experiments were performed using Molecular Operating Environment (MOE) 
2014.0901 molecular modeling software30. Homology models were built using MOE-Homology 
using AMBER99 forcefield34, which uses a dictionary to set the partial charges of atoms in amino 
acids. The final homology model was constructed using rCYP24A1 (3K9V-A) and hCYP11A1 
(3N9Y) crystal structure. Ten intermediate models were generated and the final model was taken as 
the Cartesian average of all the intermediate models. All minimisations were performed until 
RMSD gradient of 0.05 kcal mol-1Å-1 with the specified forcefield and partial charges automatically 
calculated. 
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4.2.3. Model validation 
Stereochemical quality of the polypeptide backbone and side chains was evaluated using 
Ramachandran plots obtained from the RAMPAGE server26. The compatibility of the 3D model 
with its own amino acid 1D sequence was examined using Verify 3D27. The ProSA server28 was 
used to check defaults in the three dimensional protein structure based on statistical analysis. 
Validation data from the templates (3K9V-A and 3N9Y) was used as the baseline to evaluate the 
model. 
4.2.4. Molecular dynamics simulation  
A molecular dynamics simulation was run on the hCYP27B1 model alone and the CYP27B1 model 
in complex with SDZ-88357. Both PDB files were first optimised with protein preparation wizard 
in Maestro, version 11.0.01529 by assigning bond orders, adding hydrogen, and correcting incorrect 
bond types. A default quick relaxation protocol was used to minimise the MD systems with the 
Desmond program29. In Desmond, the volume of space in which the simulation takes place (the 
global cell) is built up by regular 3D simulation boxes, which was utilised as part in this system for 
protein interactions. The orthorhombic water box (volume = 501882 Å3) allowed for a 10 Å buffer 
region between protein atoms and box sides. Overlapping water molecules were deleted, and the 
systems were neutralised with Na+ ions and salt concentration 0.15 M. Force-field parameters for 
the CYP27B1 model and the CYP27B1 model-SDZ-88357 complex were assigned using the 
OPLS_ 2005 force-field, that is, a 5 ns or 50 ns molecular dynamic run in the NPT ensemble 
(T = 300 K) at a constant pressure of 1 bar. Energy and trajectory atomic coordinate data were 
recorded at each 1.2 ns. Molecular dynamics simulation for drug design is ideally conducted at a 
temperature range of 300 -314 K. In this study, molecular dynamics simulations were done at 300 K 
and 312 K. 
4.2.5. Docking 
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT35. The 
important amino acid residues of the active pocket (Gln82, Ile131, Trp134, Met246, Ala326, 
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Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500)20 were selected and then the 
selection was extended to 12 Å in order to include in the docking site the haem iron region and the 
access tunnel to the catalytic site. A ligands database in mol2 format, prepared using MOE30, was 
used as input for the docking calculations. The iron atom of the catalytic site was set as essential 
pharmacophoric feature. Ligand docking was performed using the default values and no water 
molecules were considered. Ten output solutions were obtained from each compound and visual 
inspection in MOE was used to identify the interaction between ligand and protein. 
 
4.3. Chemistry 
4.3.1. General procedure for the preparation 4,4'-((4/3-(Pyridin-4-
ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) (1a) and (1b)  
Hydrazine monohydrate (0.18 ml, 1.7 mmol) was mixed with ethyl acetoacetate (0.22 mL, 1.7 
mmol). Then 2-hydroxy ethylammonium propionate (2-HEAP) (0.07 g, 0.5 mmol) was stirred 
under solvent free conditions for 40 min. Then, the 4-(pyridin-4-ylmethoxy)benzaldehyde31 (0.30 g, 
1.4 mmol) (3a) or the 4-(pyridin-3-ylmethoxy)benzaldehyde31 (0.40 g, 1.9 mmol) (3b) was added 
and the reaction mixture heated at 90 ℃ for 1 h. After completion, the reaction was cooled to room 
temperature, where upon it solidified. The pure product was obtained from this solid by 
recrystallisation with methanol7. 
4.3.1.1. 4,4'-((4-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) (1a).  
Tan crystalline solid obtained after recrystallization from methanol. Yield: 36%; Rf 0.34 (CH2Cl2-
CH3OH 9: 1 v/v); mp 194 - 198 °C; 
1H NMR (CDCl3): δ 8.69 (d, J = 6.0, 2H, Ar), 7.41 (d, J = 6 
Hz, 2H, Ar), 7.16 (t, J = 8.0 Hz, 2H, Ar), 6.76 (m, 2H, Ar), 5.08 (s, 2H, CH2), 4.47 (s, 1H, CH), 
2.06 (s, 6H, 2CH3). 
13C NMR (CDCl3 δ: 158.2 (C), 150.1 (CH, Ar), 146.7, 145.8, 146.3 (8 × C), 
129.3, 122.4, 121.0, 115.3, 123.4, 111.4 (6 × CH, Ar), 102.4 (CH, Ar), 68.0 (CH2), 35.4 (CH), 10.8 
(2 × CH3). LRMS (ES-TOF) m/z: 392 [M
 + H]+. HRMS (ES-TOF) Calculated mass: 392.1717 [M + 
H]+, measured mass: 392.1720 [M + H]+.  
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4.3.1.2. 4,4'-((3-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) (1b) 
Tan crystalline solid obtained after recrystallization from methanol. Yield: 25%; Rf 0.75 (EtOAc-
CH3OH 6: 1 v/v); mp 264 - 268 °C; 
1H NMR (CDCl3): δ 8.55 (d, J = 5.7 Hz, 2H, Ar), 7.40 (d, J = 
5.8 Hz, 2H, Ar), 7.15 (t, J = 8.3 Hz, 1H, Ar), 6.75 (m, 3H, Ar), 5.08 (s, 2H, CH2), 4.72 (s, 1H, CH), 
2.06 (s, 6H, 2CH3). 
13C NMR (CDCl3) δ: 158.2, 156.2 (2 × C), 150.7, 145.8 (2 × CH, Ar), 145.9, 
141.3. 129.2, 128.3, 122.42 (6 × CH, Ar), 121.0, 115.3, 111.4 (7 × C), 67.9 (CH2), 33.2 (CH), 11.2 
(2 × CH3). LRMS (ES-TOF) m/z: 392 [M
 + H]+. HRMS (ES-TOF) Calculated mass: 392.1717 [M + 
H]+, measured mass: 392.1707 [M + H]+. 
 
4.4. Enzymatic assays  
Inhibition of hCYP24A1 was performed as previously described33. Briefly, reaction mixture 
containing 0.1 μM each of Adx and AdR, 0.075 μM MBP-CYP24A1, 2.5 μM 1,25(OH)2D3, varying 
concentrations of inhibitors, and 0.5 mM NADPH was incubated at 37 °C for 25 min in a buffer of 
20 mM Tris (pH 7.5) and 125 mM NaCl. All inhibitors were dissolved in ethanol (>10 mM) or 
DMSO (>50 mM) and further diluted in ethanol to make working stock (<1 mM). The reaction was 
extracted with CH2Cl2 and analysed by HPLC. The IC50 values were determined by fitting the 
relative activity (V/V0) against the inhibitor concentration [I] using the equation V/V0 = IC50/(IC50 + 
[I]), where V and V0 are the reaction rates in the presence and absence of inhibitors. The assay for 
each compound was performed in at least duplicate and in triplicate for compounds with good 
inhibitory properties. Inhibition assay of hCYP27B1 was performed in a way similar to that of 
CYP24A1 as previously described33. 
 
 
Supplementary material 
Supplementary data associated with this article can be found, in the online version, at ……… 
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Clustal analysis; Model validation – Ramachandran, Verify3D, ProSA ; Secondary structure 
prediction; Synthesis of 2-HEAP and 3a and 3b. 
 
Acknowledgements 
We acknowledge the Cultural Attaché, Libyan Embassy, London and Misurata University for a 
PhD scholarship to Ismail M. Taban.  
 
References 
(1) Malloy, P.J.; Feldman, D. Genetic disorders and defects in vitamin D action. Endocrinol. Metab. 
Clin. North Am. 2010, 39, 333-346. 
(2) Zehnder, D.; Bland, R.; Walker, E.A.; Bradwell, A.R.; Howie, A.J.; Hewison, M.; Stewart, P.M. 
Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J. Am. Soc. 
Nephrol. 1999, 10, 2465–2473.  
(3) Cross H.S. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant 
cells: modification of expression by epigenetic mechanisms and dietary substances. Nutr. Rev. 
2007, 65, S108-S112. 
(4) Bikle, D.D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 
2014, 21, 319-329. 
(5) Pike, J.W.; Meyer, M.B.; Bishop, K.A. Regulation of target gene expression by the vitamin D 
receptor – an update on mechanisms. Rev. Endocr. Metab. Disord. 2012, 13, 45-55. 
(6) de Brito Galvao, J.F.; Nagode, L.A.; Shenck, P.A.; Chew, D.J. Calcitriol, calcidiol, parathyroid 
hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. J. Vet. Emerg. 
Crit. Care 2013, 23, 134-162 
(7) DeLuca, H.F. Overview of the general physiologic features and functions of vitamin D. Am. J. 
Clin. Nutr. 2004, 80, 1689-1696. 
23 
 
(8) Lopes N.; Sousa, B.; Martins, D.; Gomes, M.; Vieira, D.; Veronese, L.A.; Milanezi, F.; Paredes, 
J.; Costa, J.L.; Schmitt, F. Alterations in vitamin D signalling and metabolic pathways in breast 
cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant 
breast lesions. BMC Cancer 2010, 10, 483-492. 
(9) Matusiak, D.; Murillo, G.; Carroll, R.E.; Mehta, R.G.; Benya, R.V. Expression of vitamin D 
receptor and 25-hydroxyvitamin D3-1α-hydroxylase in normal and malignant human colon. Cancer 
Epidemiol. Biomark. Prev. 2005, 14, 2370–2376. 
(10) Chen, T.C.; Wang, L.; Whitlatch, L.W.; Flanagan, J.N.; Holick, M.F. Prostatic 25-
hydroxyvitamin D-1α-hydroxylase and its implication in prostate cancer. J. Cell. Biochem. 2003, 
88, 315–322. 
(11) Brożyna, A.A.; Jochymski, C.; Janjetovic, Z.; Jóźwicki, W.; Tuckey, R.C.;  Slominski, A.T. 
CYP24A1 expression inversely correlates with melanoma progression: clinic-pathological studies. 
Int. J. Mol. Sci. 2014, 15, 19000-19017. 
(12) Schuster, I.; Egger, H.; Bikle, D.; Herzig, G.; Reddy, G.S.; Stuetz, A.; Stuetz, P.; Vorisek, G. 
Selective inhibition of vitamin D hydroxylase in human keratinocytes. Steroids 2001, 66, 409-422. 
(13) Schuster, I.; Astecker, N.; Egger, H.; Herzig, G.; Reddy, S.; Schuessler, M.; Vorisek, G.; 
Wachter, C. Inhibitors of vitamin D hydroxylases: mechanistic tools and therapeutic aspects. In: 
Stolzt, D. V, Ed.; New topics in vitamin D research; Nova Science: New York, 2006; pp 95–96. 
(14) Salvo Ferla, S.; Aboraia, A. S.; Brancale, A.; Pepper, C. J.; Zhu, J.; Ochalek, J. T.; DeLuca, H. 
F.; Simons, C. Small molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): 
synthesis and biological evaluation. J. Med. Chem. 2014, 57, 7702–7715. 
(15) Salvo Ferla, S.; Gomaa, S.M.S.; Brancale, A.; Zhu, J.; Ochalek, J. T.; DeLuca, H. F.; Simons, 
C. Novel styryl-indoles as small molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase 
(CYP24A1): synthesis and biological evaluation. Eur. J. Med. Chem. 2014, 87, 39-51. 
24 
 
(16) Aboraia, A.S.; Yee, S.W.; Gomaa, M.S.; Shah, N.; Robotham, A.C.; Makowski, B.; Prosser, 
D.; Brancale, A.; Jones, G.; Simons, C. Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-
imidazol-1-yl)-2-phenylethyl)arylamides. Bioorg. Med. Chem., 2010, 18, 4939-4946. 
(17) Taban, I.M.; Zhu, Z.; DeLuca, H.F.; Simons, C. Synthesis, molecular modelling and CYP24A1 
inhibitory activity of novel of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides. 
Bioorg. Med.Chem. 2017, DOI: 10.1016/j.bmc.2017.05.055 
(18) Chiellini, G.; Rapposelli, S.; Zhu, J.; Massarelli, I.; Saraceno, M.; Bianucci, A. M.; Plum, L. 
A.; Clagett-Dame, M.; DeLuca, H. F. Synthesis and biological activities of vitamin D-like inhibitors 
of CYP24 hydroxylase. Steroids 2012, 77, 212−223.  
(19) Kahraman, M.; Sinishtaj, S.; Dolan, P. M.; Kensler, T. W.; Peleg, S.; Saha, U.; Chuang, S. S.; 
Bernstein, G.; Korczak, B.; Posner, G. H. Potent, selective and low-calcemic inhibitors of CYP24 
hydroxylase: 24-sulfoximine analogues of the hormone 1α,25-dihydroxyvitamin D3. J. Med. Chem. 
2004, 47, 6854−6863.  
(20) Gomaa, M. S.; Brancale, A.; Simons, C. Homology model of 1,25-dihydroxyvitamin D3 24-
hydroxylase cytochrome P450 24A1 (CYP24A1): active site architecture and ligand binding. J. 
Steroid Biochem. Mol. Biol. 2007, 104, 53–60. 
(21) Zalewski, A.; Ma, N.S.; Legeza, B.; Renthal, N.; Flück, C.E.; Pandey, A.V. Vitamin D-
dependent rickets type 1 caused by mutations in CYP27B1 affecting protein interactions with 
adrenodoxin. J. Clin. Endocrinol. Metab. 2016, 101, 3409-3418. 
(22) Gasteiger, E.; Gattiker, A.; Hoogland, C.; Ivanyi, I.; Appel, R.D.; Bairoch, A. ExPASy: the 
proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003, 31, 3784–
3788. 
(23) Schaffer, A.A.; Aravind, L.; Madden, T.L.; Shavirin, S.; Spouge, J.L.; Wolf, Y.I.; Koonin, 
E.V.; Altschul, S.F. Improving the accuracy of PSI-BLAST protein database searches with 
composition- based statics and other refinements. Nucleic acids Res. 2001, 29, 2994-3005. 
[http://blast.ncbi.nim.hih.gov] 
25 
 
(24) RCSB Protein Data Bank (PDB) http://www.rcsb.org/pdb. 
(25) Sievers, F.; Wilm, A.; Dineen, D.G.; Gibson, T.J.; Karplus, K.; Li, W.; Lopez, R.; McWilliam, 
H.; Remmert, M.; Söding, J.; Thompson, J.D.; Higgins, D.G. Fast, scalable generation of high-
quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011, 7, 539.  
(26) RAMPAGE Server http://ravenbioccam.ac.uk/rampage.php 
(27) Bowie, U.J.; Eisenberg, D. Method to identify protein sequence that fold into a known three 
dimensional structure. Science 1991, 253, 164-170. 
(28) Weiderstein, M.; Sippl, M.J. ProSA-web: interactive web service for the recognition of errors 
in three dimensional structures of proteins. Nucleic Acid Res. 2007, 35, 407-410. 
(29) Bowers, K.J.; Chow, E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; 
Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; Salmon, J.K.; Shan, Y.; Shaw, D.E. Scalable 
algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 
ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida, 2006, November 11-17 
[https://www.schrodinger.com/maestro] 
(30) Molecular Operating Environment (MOE 2014.0901) Chemical Computing Group Inc, 
Montreal Quebec Canada http://www.chemcomp.com.  2014.0901. 
(31) Zhou, Z.; Zhang, J. An efficient and green one-pot three-component synthesis of 4,4′-
(arylmethylene)bis(1H-pyrazol-5-ol)s catalyzed by 2-hydroxy ethylammonium propionate. Green 
Chem. Lett. Rev. 2014, 7, 18-23.  
(32) Sobhani, S.; Nasseri, R.; Honarmand, M. 2-Hydroxyethylammonium acetate as a reusable and 
cost-effective ionic liquid for the efficient synthesis of bis(pyrazolyl)methanes and 2-pyrazolyl-1-
nitroalkanes. Can. J. Chem. 2012, 90, 798-804. 
(33) Zhu, J.; Barycki, R.; Chiellini, G.; DeLuca, H. F. Screening of selective inhibitors of 1α,25-
dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia 
coli. Biochemistry 2010, 49, 10403−10411.  
26 
 
(34) Weiner, S.J.; Kollman, P.A.; Nguyen, D.T. An all atom forcefield for simulations of proteins 
and nucleic acids. J. Comput. Chem. 1986, 7, 230–252. 
(35) LeadIt http://www.biosolveit.de/ 
 
 
 
 
 
 
 
 
 
 
 
 
